|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using five bioinformatics analysis software, we identified Golgi protein 73 (GP73) as a putative target of microRNA-27b (miR-27b), which is closely related to various biological processes or diseases such as bone metabolism disease, adipose cell and muscle cell development, pulmonary hypertension, cervical cancer, and breast cancer.
|
30418194 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Considered together, our study indicated that the overexpression of miR-206, miR-133a, and miR-27b might be potential biomarkers for prognosis and therapeutic strategies in breast cancer.
|
30779469 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To clarify this dichotomous role in breast cancer, miR-23b and miR-27b were knocked out using CRISPR/Cas9 gene knockout technology, and the role of endogenous miR-23b and miR-27b was examined in a breast cancer model system in vitro and in vivo.
|
31253120 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further, miR-27b was identified as a promising molecular biomarker in chemoresistance, clinicopathological features, and prognosis for breast cancer patients.
|
29416005 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We sought to characterize the role of miR-27b in breast cancer by identifying novel transcripts under its control.
|
30012170 |
2018 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, the expression levels of miR-27b-3p were lower in the breast cancer tissues from tamoxifen-resistant patients compared with that from untreated-tamoxifen patients.
|
27809310 |
2016 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MiR-27b is epigenetically downregulated in tamoxifen resistant breast cancer cells due to promoter methylation and regulates tamoxifen sensitivity by targeting HMGB3.
|
27363334 |
2016 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
More importantly, reduction in miR98 and miR27b enhances the epithelial-mesenchymal transition (EMT) of breast cancer cells, and thus promotes breast cancer metastasis.
|
26244871 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we identified microRNA-27b (miR-27b) as a key regulator for the generation of a side-population in breast cancer cells that showed CSC properties, and also found that the anti-type II diabetes (T2D) drug metformin reduced this side-population via miR-27b-mediated repression of ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1), which is involved in T2D development.
|
26065921 |
2015 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We showed the clinical relevance of the expression of these miRNAs and showed that high expression of miR-23b and miR-27b correlates with poor outcome in breast cancer.
|
23338610 |
2013 |